TCRR - TCR² Therapeutics establishes commercial-scale cell therapy manufacturing facility

TCR2 Therapeutics (TCRR)  announces that it has signed a long-term, full-building lease with Alexandria Real Estate Equities (ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturing Practice ((cGMP)) build-out.The facility is expected to accelerate the company’s commercial-scale manufacturing timelines with production anticipated in 2023.The company also announces the appointment of Aaron Vernon as Vice President of Technical Operations.Vernon held senior positions including Vice President of Global Technical Operations and Vice President of Engineering & Supply Chain at Autolus Therapeutics (AUTL).Shares down nearly 1% premarket.

For further details see:

TCR² Therapeutics establishes commercial-scale cell therapy manufacturing facility